AzTrials
AzTrials

Major Depressive DisorderPhase 2NCT01558063

Ketamine in the Treatment of Depression

A Phase 2 study testing Ketamine, Saline and Magnetic Resonance Imaging (MRI) in people with Major Depressive Disorder, run by Columbia University at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Depressed patients will be offered experimental treatment with a new, potentially fast-acting antidepressant called ketamine while being scanned by magnetic resonance imaging (MRI) to measure the chemical effect of the drug. Ketamine will be given in a dose of 0.0 (placebo), 0.1, 0.2, 0.3, 0.4, or 0.5 mg/kg. Read more about this study

Who is it for?
Ages 18 to 65 yearsHealthy volunteers can take part
Conditions the study is for
Major Depressive Disorder
What is being tested?
Ketamine, Saline and Magnetic Resonance Imaging (MRI)
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
38 participants
Where
1 siteUnited States
Study dates
Feb 2012to Oct 2019
Phase
Phase 2
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Patient Inclusion Criteria:

  • Patient suffering from a major depressive episode (MDE) as part of an major depressive disorder (MDD). Patients may be psychiatric medication-free or, if on psychiatric medications, not responding adequately.
  • Patient scores at least 22 on the Montgomery-Åsberg Depression Rating Scale (MADRS)
  • Age range 18-65 years
  • Patient is off all psychotropic and other types of drugs likely to interact with glutamate for at least 14 days before starting the study with an exception of chloral hydrate or short acting benzodiazepines for distressing anxiety or insomnia
  • Subject is likely to be able to tolerate a medication washout
  • Female subjects of child-bearing potential must be using an acceptable method of birth control throughout the study.
  • Must be enrolled in New York Psychiatric Institute (NYSPI) study #4815

Patient Exclusion Criteria:

  • Lifetime history of schizophrenia,schizoaffective illness, Bipolar Disorder, or psychosis.
  • First-degree relative with schizophrenia, schizoaffective disorder, or bipolar disorder if the subject is less than 33 years old
  • Significant uncontrolled physical illness particularly if it may affect the brain or glutamatergic system including blood dyscrasias lymphomas, hypersplenism, endocrinopathies, renal failure or severe chronic obstructive lung disease, autonomic neuropathies and active malignancy.
  • Subjects will be excluded for baseline hypertension (BP>140/90) or significant history of cardiovascular illness
  • Significant ECG abnormalities
  • Lacks capacity to consent
  • Patients who are actively suicidal as defined by a suicidal ideation score of 4 or 5 or suicidal behavior score > 0 on the Columbia Suicide Severity Rating Scale (C-SSRS) at in-person screening interview will be excluded from participating as outpatients and may only participate as inpatients if the independent inpatient treatment team agrees with the plan to enroll the patient.
  • Electroconvulsive therapy (ECT) within the last 3 months for this episode
  • Pregnancy or plans to conceive during the course of study participation
  • Heart pacemaker, body implant or other metal in body
  • A neurological disease or prior head trauma with evidence of cognitive impairment.
  • Patients who are responding satisfactorily to antidepressant medications because they will not be washed-out for purposes of this study
  • Claustrophobia sufficient to preclude MRI
  • Irremovable medicinal patch
  • Prior ineffective trial of, or adverse effect to, ketamine
  • Subjects judged unlikely to be able to tolerate a psychoactive medication washout of 14 days
  • Inadequate understanding of English
  • IV drug use or history of ketamine use as a recreational drug ≥ 2 times or an adverse reaction to ketamine

Control Inclusion Criteria:

  • Age 18-65
  • Physically healthy
  • Absence of an Axis I diagnosis (specific phobia acceptable). Absence of Borderline Personality Disorder and Antisocial Personality Disorder.
  • Not on any medications known to affect glutamatergic functioning
  • Female subjects of child-bearing potential must be using an acceptable method of birth control throughout the study.
  • Must be enrolled in NYSPI protocol #4815

Control Exclusion Criteria:

  • First degree relative with MDD; first degree relative with Schizophrenia, Schizoaffective Disorder, Bipolar disorder, if the subject is less than 33 years old, and therefore still at significant risk
  • Significant active physical illness particularly if it may affect the brain or glutamatergic system including blood dyscrasias lymphomas, hypersplenism, endocrinopathies, renal failure or severe chronic obstructive lung disease,autonomic neuropathies and active malignancy.
  • Subjects will be excluded for baseline hypertension (BP>140/90) or significant history of cardiovascular illness.
  • Significant ECG abnormalities
  • Pregnancy or plans to conceive during the course of study participation
  • Heart pacemaker, body implant or other metal in body
  • A neurological disease or prior head trauma with evidence of cognitive impairment.
  • Claustrophobia sufficient to preclude MRI
  • Irremovable Medicinal patch
  • Inadequate understanding of English
  • Lifetime history of substance dependence,current or past substance abuse will be excluded; IV drug use or history of ketamine use as a recreational drug ≥ 2 times or an adverse reaction to ketamine will be excluded.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • New York State Psychiatric Institute

    New York, New York, 10032

Other trials in United States

About this study

Official title: The Antidepressant Action of Ketamine: Brain Chemistry

Depressed patients will be offered experimental treatment with a new, potentially fast-acting antidepressant called ketamine while being scanned by magnetic resonance imaging (MRI) to measure the chemical effect of the drug. Ketamine will be given in a dose of 0.0 (placebo), 0.1, 0.2, 0.3, 0.4, or 0.5 mg/kg. If a patient does not respond to ketamine after the first infusion, it may be because s/he received ketamine placebo or the dose of ketamine was too low. In that case, an optional second scan and infusion of active ketamine (0.5 mg/kg) will be offered. This second scan will occur no later than weeks after the first scan/infusion (as scheduling permits). There is no guarantee that the patient will respond to the second ketamine infusion. Patients enrolled in the study are eligible for up to 6 months treatment with their study psychiatrist after the ketamine infusion(s).

Healthy Volunteers: Healthy controls will receive an infusion of ketamine at a single dose (0.5 mg/kg). Volunteers will only receive one MRI scan and infusion.

Read the detailed description

Major depressive disorder (MDD) is a common illness, affecting over 14 million American adults each year. MDD is a leading cause of disability worldwide, and is responsible for huge workplace and healthcare costs. The several week delay between onset of treatment and improvement in MDD symptoms with currently available treatments further increases the burden of the disorder. Shortening this delay is a major unmet challenge in the treatment of MDD. Studies report that a single intravenous low dose of a drug called ketamine can bring about substantial improvement in depression in hours, even in patients that have not improved with other antidepressant treatments. Certain aspects of ketamine's drug action are fairly well understood, but the question remains of how these properties relate to antidepressant effect. The investigator's preliminary data support the rapid antidepressant benefit from ketamine. The investigators have used a scanner to measure the effects of ketamine on two major brain chemical transmitters and found that it causes a significant increase (more than 60%) in glutamate (Glu) and gamma aminobutyric acid (GABA) levels in the front of the brain. The investigators hypothesize that this increase in Glu and GABA levels, is responsible for the antidepressant action of the medication. Knowing how ketamine works could help to develop better medications that can be used orally and used for maintenance of the improvement seen with ketamine. The objective of the proposed dose finding study is to examine the relationship between the ketamine-induced improvement of MDD and the Glu and GABA responses to ketamine and to compare the Glu and GABA responses to ketamine in MDD and healthy subjects to better understand the pathophysiology of MDD. To achieve these aims this the investigators propose a randomized, placebo-controlled, double blind study with several different doses of ketamine. The investigators will conduct MRI scans to measure Glu and GABA before and during the ketamine treatment.

Being tested
Ketamine, Saline, Magnetic Resonance Imaging (MRI)
Keywords
Ketamine, Major Depressive Disorder, Treatment, Depression
Medical subject headings
Depressive Disorder, Major, Depression

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • KetamineDrug

    Also called Ketalar

    Single dose of 0.1, 0.2, 0.3, 0.4 or 0.5 mg/kg of ketamine given intravenously over 40 minutes.

  • SalineDrug

    Also called Saline solution

    Single infusion of saline given intravenously over 40 minutes.

  • Magnetic Resonance Imaging (MRI)Procedure or surgery

    90-minute scan during the 40-minute infusion.

Study groups in NCT01558063
Study groupRoleWhat they receive
Ketamine Dose 1Active comparator0.1 mg/kg, IV (in the vein) of Ketamine and MRI scan
Receives: Drug: Ketamine; Procedure: Magnetic Resonance Imaging (MRI)
Ketamine Dose 2Active comparator0.2 mg/kg, IV (in the vein) of Ketamine and MRI scan
Receives: Drug: Ketamine; Procedure: Magnetic Resonance Imaging (MRI)
Ketamine Dose 3Active comparator0.3 mg/kg, IV (in the vein) of Ketamine and MRI scan
Receives: Drug: Ketamine; Procedure: Magnetic Resonance Imaging (MRI)
Ketamine Dose 4Active comparator0.4 mg/kg, IV (in the vein) of Ketamine and MRI scan
Receives: Drug: Ketamine; Procedure: Magnetic Resonance Imaging (MRI)
Ketamine Dose 5Active comparator0.5 mg/kg, IV (in the vein) of Ketamine and MRI scan
Receives: Drug: Ketamine; Procedure: Magnetic Resonance Imaging (MRI)
Saline SolutionPlacebo comparatorSaline infused over 40 minutes and MRI scan
Receives: Drug: Saline; Procedure: Magnetic Resonance Imaging (MRI)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of Responders 24-hours Post-ketamine Infusion

    The quantitative depressive symptom ratings were collected at Baseline, Day 1 (post ketamine), Day 3 using HDRS-24 (a 24-item questionnaire used to provide an indication of depression, and as a guide to evaluate recovery). The total score can range from 0 to a maximum score of 15 with a higher score indicating a worse outcome. A "responder" was defined as an individual exhibiting a reduction in the HDRS score from baseline to 24 hours (day 1) post-treatment, and all other individuals were classified as non-responders.

    Measured: Day 1 (post ketamine)

Secondary outcomes (2)
  1. Change in Glutamate Levels

    The dose-response curve as it refers to ketamine inducing a dose-dependent increase in glutamate levels with 1H Magnetic Resonance Spectroscopy (MRS) will be analyzed.

    Measured: Baseline and 120 minutes after infusion

  2. Change in Gamma-Amino Butyric Acid (GABA) Levels

    The dose-response curve as it refers to ketamine inducing a dose-dependent increase in GABA levels measured with 1H Magnetic Resonance Spectroscopy (MRS) will be analyzed.

    Measured: Baseline and 120 minutes after infusion

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 Mar 2012 (estimated)
  2. Study startFeb 2012
  3. Primary completionMay 2015
  4. Study completionOct 2019

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Investigator, Outcomes assessor
Enrolment
38 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01558063
Sponsor's protocol ID
NYSPI 6460
Other IDs
5R01MH093637-03
Status last verified
Dec 2019
First submitted
16 Mar 2012
Last updated
10 Dec 2019
Data monitoring committee
Yes
Individual data sharing
No

Publications

  • Strong CE, Kabbaj M. Neural Mechanisms Underlying the Rewarding and Therapeutic Effects of Ketamine as a Treatment for Alcohol Use Disorder. Front Behav Neurosci. 2020 Dec 10;14:593860. doi: 10.3389/fnbeh.2020.593860. eCollection 2020.

    PubMed 33362485
  • Milak MS, Rashid R, Dong Z, Kegeles LS, Grunebaum MF, Ogden RT, Lin X, Mulhern ST, Suckow RF, Cooper TB, Keilp JG, Mao X, Shungu DC, Mann JJ. Assessment of Relationship of Ketamine Dose With Magnetic Resonance Spectroscopy of Glx and GABA Responses in Adults With Major Depression: A Randomized Clinical Trial. JAMA Netw Open. 2020 Aug 3;3(8):e2013211. doi: 10.1001/jamanetworkopen.2020.13211.

    PubMed 32785636

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Ketamine, Saline and Magnetic Resonance Imaging (MRI) in people with Major Depressive Disorder, run by Columbia University at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 10 Dec 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 16 Jul 2019). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of Responders 24-hours Post-ketamine Infusion (time frame: Day 1 (post ketamine)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01558063, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Dec 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in